Wednesday, 20 January 2021
Sign Up Now!
To sign up for our newsletter or print publications, please enter your contact information below.
First Name
*
Last Name
*
Email Address
*
Email Address (Verify)
*
JHOP Print Edition
We will request your mailing address on the next page.
JHOP E-Newsletters & Communications
TOP Print Edition
We will request your mailing address on the next page.
TOP E-Newsletters & Communications
I have reviewed and consent to the terms of
JHOP
's
Privacy Policy
, and
JHOP
has my permission to retain my information in its database, and to forward pertinent communications to me.
Click Here to
Subscribe
Breaking
News, Updates,
& More
Stay Up
to Date
Home
Issues
2020
December 2020, Vol 10, No 6
October 2020, Vol 10, No 5
August 2020, Vol 10, No 4
June 2020, Vol 10, No 3
April 2020 Vol 10, No 2
February 2020 Vol 10, No 1
2019
December 2019 Vol 9, No 4
September 2019 Vol 9, No 3
June 2019 Vol 9, No 2
March 2019 Vol 9, No 1
2018
December 2018 Vol 8, No 4
September 2018 Vol 8, No 3
June 2018 Vol 8, No 2
March 2018 Vol 8, No 1
2017
December 2017 Vol 7, No 4
September 2017 Vol 7, No 3
June 2017 Vol 7, No 2
March 2017 Vol 7, No 1
Issue Archive
Special Issues
Supplements
2020 Year in Review - Biosimilars
2020 Year in Review - Acute Myeloid Leukemia
2020 Year in Review - Cholangiocarcinoma
2020 Year in Review - Lung Cancer
2020 Year in Review - Neuroendocrine Tumors
2020 Year In Review - Ovarian Cancer
Guide to New FDA Approvals
2019 Fourth Annual Guide
2018 Third Annual Guide
2017 Second Annual Guide
2016 First Annual Guide
Categories
Conference Correspondent
ASCO 2020 - Lung Cancer
ASH 2020 - Multiple Myeloma
ESMO 2020 Highlights
SABCS 2020 Highlights
Web Exclusives
All Web Exclusives
Drug Updates
FDA Approvals
In the News
Online First
Press Releases
Media Library
Videos
Audiocasts
Melanoma Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview Guidelines
Letters to the Editor Instructions
Peer Review Application
Submit a Manuscript
About
About JHOP
About GreenhillHC
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Advertise
Phoebe Starr
Authored Items
Adjuvant Abemaciclib plus Endocrine Therapy Game-Changer in High-Risk, HR-Positive, HER2-Negative Early Breast Cancer
Phoebe Starr
Web Exclusives
in
ESMO 2020
Atezolizumab, Vemurafenib, and Cobimetinib Triplet Therapy Improves PFS in BRAF-Positive Melanoma
Phoebe Starr
Web Exclusives
in
AACR Highlights
Why Is COVID-19 More Aggressive in Certain Patients with Cancer?
Phoebe Starr
TOP - July 2020, Vol 13, No 4
in
AACR Highlights
ctDNA May Be a Biomarker for Postsurgery MRD Positivity and Relapse in Patients with NSCLC
Phoebe Starr
TOP - July 2020, Vol 13, No 4
in
AACR Highlights
Atezolizumab, Vemurafenib, and Cobimetinib Triplet Therapy Improves PFS in BRAF-Positive Melanoma
Phoebe Starr
TOP - July 2020, Vol 13, No 4
in
AACR Highlights
Two Ways to Target Tumors with KRAS Mutations
Phoebe Starr
TOP - July 2020, Vol 13, No 4
in
AACR Highlights
Targeted Therapy with Olaparib Beneficial in Metastatic Prostate Cancer with Gene Mutations
Phoebe Starr
Web Exclusives
in
ESMO
Ceritinib Effective in Treating Brain Metastases in NSCLC
Phoebe Starr
Web Exclusives
in
ESMO
Paradigm Shift: PARP Inhibitors Should Be Offered to All Patients with Ovarian Cancer
Phoebe Starr
Web Exclusives
in
ESMO
Long-Term Data Confirm Survival Benefit for Pembrolizumab in Advanced NSCLC
Phoebe Starr
Web Exclusives
in
Lung Cancer
Adding CDK4/6 Inhibitor to Endocrine Therapy Improves Survival in Advanced Breast Cancer: New Standard of Care
Phoebe Starr
Web Exclusives
in
ESMO
,
Breast Cancer
FDA Unveils Pilot Program to Expand Access to Investigational Oncology Drugs
Phoebe Starr
Web Exclusives
in
ASCO
MURANO: Venetoclax-Rituximab at Fixed Duration Beats Chemoimmunotherapy in Relapsed/Refractory CLL
Phoebe Starr
JHOP - March 2019 Vol 9, No 1
in
ASH
Researchers Identify First Mutation to Explain Resistance to Venetoclax
Phoebe Starr
JHOP - March 2019 Vol 9, No 1
in
ASH
Checkpoint Inhibitor a New Approach to Jump-Start a Waning Response to CAR T-Cell Therapy
Phoebe Starr
JHOP - March 2019 Vol 9, No 1
in
Immunotherapy
,
ASH
Durable Responses to CAR T-Cell Therapy in B-Cell Lymphomas
Phoebe Starr
JHOP - March 2019 Vol 9, No 1
in
Lymphoma
,
ASH
Explosive Development of BCMA CAR T-Cell Therapy for Multiple Myeloma
Phoebe Starr
Web Exclusives
in
Immunotherapy
,
Multiple Myeloma
Brigatinib, Next-Generation ALK Inhibitor, Improves Survival versus Crizotinib in Patients with NSCLC and ALK Mutation
Phoebe Starr
Web Exclusives
in
Lung Cancer
5 mg Tamoxifen as Effective as 20 mg Daily in Early Localized Breast Cancer
Phoebe Starr
Web Exclusives
in
Breast Cancer
TLR9 Agonist plus Immunotherapy May Overcome Resistance to PD-1 Inhibition
Phoebe Starr
Web Exclusives
in
Emerging Therapies
Nivolumab plus Ipilimumab Combo Controls Brain Metastases in Patients with Skin Cancer
Phoebe Starr
Web Exclusives
in
Immunotherapy
Less Is More: Six Months of Traxtuzumab Equivalent to 12 Months in HER2-Positive Breast Cancer
Phoebe Starr
Web Exclusives
in
Breast Cancer
Immunotherapy Combinations “Raising the Bar”
Phoebe Starr
Web Exclusives
in
Immunotherapy
Ivosidenib a New Standard of Care for Relapsed or Refractory AML with IDH1 Mutation
Phoebe Starr
Web Exclusives
in
Emerging Therapies
CAR T-Cell Manufacturing Process Depends on Good-Quality T-Cells
Phoebe Starr
Web Exclusives
in
Immunotherapy
Obinutuzumab Prolongs Survival in Follicular Lymphoma
Phoebe Starr
Web Exclusives
in
Conference Correspondent
,
ASH
CAR T-Cell Therapy Succeeds in Aggressive Lymphoma
Phoebe Starr
Web Exclusives
in
Conference Correspondent
,
ASH
R-CHOP Prevails Over Dose-Adjusted EPOCH-R as Standard of Care for Diffuse Large B-Cell Lymphoma
Phoebe Starr
Web Exclusives
in
Conference Correspondent
,
In the News
Strategies to Reduce the Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Phoebe Starr
Web Exclusives
in
Conference Correspondent
,
In the News
Last modified: June 18, 2020
Home
Issues
2020
December 2020, Vol 10, No 6
October 2020, Vol 10, No 5
August 2020, Vol 10, No 4
June 2020, Vol 10, No 3
April 2020 Vol 10, No 2
February 2020 Vol 10, No 1
2019
December 2019 Vol 9, No 4
September 2019 Vol 9, No 3
June 2019 Vol 9, No 2
March 2019 Vol 9, No 1
2018
December 2018 Vol 8, No 4
September 2018 Vol 8, No 3
June 2018 Vol 8, No 2
March 2018 Vol 8, No 1
2017
December 2017 Vol 7, No 4
September 2017 Vol 7, No 3
June 2017 Vol 7, No 2
March 2017 Vol 7, No 1
Issue Archive
Special Issues
Supplements
2020 Year in Review - Biosimilars
2020 Year in Review - Acute Myeloid Leukemia
2020 Year in Review - Cholangiocarcinoma
2020 Year in Review - Lung Cancer
2020 Year in Review - Neuroendocrine Tumors
2020 Year In Review - Ovarian Cancer
Guide to New FDA Approvals
2019 Fourth Annual Guide
2018 Third Annual Guide
2017 Second Annual Guide
2016 First Annual Guide
Categories
Conference Correspondent
ASCO 2020 - Lung Cancer
ASH 2020 - Multiple Myeloma
ESMO 2020 Highlights
SABCS 2020 Highlights
Web Exclusives
All Web Exclusives
Drug Updates
FDA Approvals
In the News
Online First
Press Releases
Media Library
Videos
Audiocasts
Melanoma Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview Guidelines
Letters to the Editor Instructions
Peer Review Application
Submit a Manuscript
About
About JHOP
About GreenhillHC
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Advertise